Phaseline

Companies › POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
[Lu-177]-PNT2002
Lutetium-177 labeled PSMA targeted radioligand therapy
PSMAPhase 3Metastatic Castration-Resistant Prostate CancerMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04647526[Lu-177]-PNT2002Phase 3Metastatic Castration-Resistant Prostate CancerOncologyMar 2028

Targets

PSMA (1)

Companies with the same targets

Clarity Pharmaceuticals C Ray Therapeutics Nova Therapeutics Eli Lilly Fusion Pharmaceuticals Lantheus Medical Imaging Sinotau Pharmaceutical Group Norroy Bioscience Inovio Pharmaceuticals Curium US

Companies built like this

Curium US Norroy Bioscience Fusion Pharmaceuticals Clarity Pharmaceuticals Verity Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.